LivaNova PLC (LIVN)

LivaNova to Announce Second-Quarter 2026 Results

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2026 results...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

– Presentation at SLEEP 2026 illustrates ability to convert non-responders into responders using personalized programming LivaNova PLC (Nasdaq:...

Form 144 - Report of proposed sale of securities

Jette Nygaard-Andersen Joins LivaNova Board as a New Director

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the election of Jette Nygaard-Andersen to the Company’s Board...

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

LivaNova Appoints Anne Liddy as Chief Legal Officer

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer...

Form SD - Specialized disclosure report

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities